Diffusion Pharmaceuticals (NASDAQ:DFFN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFNFree Report) in a report published on Monday. The firm issued a hold rating on the stock.

Diffusion Pharmaceuticals Trading Up 11.7 %

NASDAQ DFFN opened at $4.40 on Monday. The company’s 50 day simple moving average is $4.64 and its 200 day simple moving average is $5.74. Diffusion Pharmaceuticals has a 12 month low of $2.76 and a 12 month high of $7.40.

Institutional Trading of Diffusion Pharmaceuticals

A hedge fund recently bought a new stake in Diffusion Pharmaceuticals stock. JPMorgan Chase & Co. acquired a new position in shares of Diffusion Pharmaceuticals Inc. (NASDAQ:DFFNFree Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,491 shares of the company’s stock, valued at approximately $106,000. JPMorgan Chase & Co. owned 0.42% of Diffusion Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 9.95% of the company’s stock.

About Diffusion Pharmaceuticals

(Get Free Report)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Featured Articles

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.